ID   SK-N-BE(2)-M17
AC   CVCL_0167
SY   BE(2)-M17; BE(2)M17; BE(2)M-17; BE2-M17; BE2M17
DR   BTO; BTO:0002104
DR   CLO; CLO_0001916
DR   MCCL; MCC:0000059
DR   CLDB; cl407
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2267
DR   BioSample; SAMN03471024
DR   BioSample; SAMN03472366
DR   CCLE; BE2M17_AUTONOMIC_GANGLIA
DR   CCRID; 3111C0001CCC000076
DR   Cell_Model_Passport; SIDM01229
DR   Cosmic; 753616
DR   Cosmic; 1167416
DR   Cosmic-CLP; 753616
DR   DepMap; ACH-002217
DR   ECACC; 95011816
DR   GDSC; 753616
DR   GEO; GSM1669614
DR   JCRB; JCRB9131
DR   JCRB; NIHS0221
DR   LINCS_LDP; LCL-1972
DR   Lonza; 1236
DR   NCBI_Iran; C614
DR   PharmacoDB; BE2M17_85_2019
DR   Wikidata; Q54954446
RX   PubMed=2535691;
RX   PubMed=10485488;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=26342562;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-n-be-2-m17-human-neuroblastoma-cell-line
WW   http://www.cellresource.cn/fdetail.aspx?id=76
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-531.
CC   Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
CC   Doubling time: 20-24 hours (ECACC).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Homozygous for TP53 p.Cys135Phe (c.404G>T) (ClinVar=VCV000376559) (Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=3.92%; Native American=1.22%; East Asian, North=3.24%; East Asian, South=0%; South Asian=6.24%; European, North=21.38%; European, South=64% (PubMed=30894373).
CC   Discontinued: JCRB; JCRB9131; true.
CC   Discontinued: JCRB; NIHS0221; true.
CC   Derived from metastatic site: Bone marrow.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; ECACC; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,11 (CCRID)
ST   D16S539: 11 (ATCC; Cosmic-CLP; ECACC; JCRB; PubMed=25877200)
ST   D18S51: 14 (PubMed=25877200)
ST   D18S51: 16,26 (CCRID)
ST   D19S433: 12,13
ST   D21S11: 30,32.2
ST   D2S1338: 17,23 (PubMed=25877200)
ST   D2S1338: 23 (CCRID)
ST   D3S1358: 19
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 22,25
ST   Penta D: 13,14
ST   Penta E: 14,18
ST   TH01: 6
ST   TPOX: 8,11 (ATCC; Cosmic-CLP; ECACC; JCRB; PubMed=25877200)
ST   TPOX: 11 (CCRID)
ST   vWA: 17,18 (Cosmic-CLP; JCRB)
ST   vWA: 18 (ATCC; CCRID; ECACC; PubMed=25877200)
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0528 ! SK-N-BE(2)
SX   Male
AG   1Y10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-10-20; Version: 26
//
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
//
RX   PubMed=10485488;
RA   Glick R.D., Swendeman S.L., Coffey D.C., Rifkind R.A., Marks P.A.,
RA   Richon V.M., La Quaglia M.P.;
RT   "Hybrid polar histone deacetylase inhibitor induces apoptosis and
RT   CD95/CD95 ligand expression in human neuroblastoma.";
RL   Cancer Res. 59:4392-4399(1999).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=26342562; DOI=10.1016/j.scr.2015.08.008;
RA   Ross R.A., Walton J.D., Han D., Guo H.-F., Cheung N.-K.V.;
RT   "A distinct gene expression signature characterizes human
RT   neuroblastoma cancer stem cells.";
RL   Stem Cell Res. 15:419-426(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//